| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2013 | EP2543374A2 Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient |
| 01/09/2013 | EP2543373A1 Compound pharmaceutical composition of levoamlodipine |
| 01/09/2013 | EP2543372A1 Medicament for the treatment of liver cancer |
| 01/09/2013 | EP2543371A1 Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| 01/09/2013 | EP2543370A1 Compositions and Methods for Treating Herpes Simplex Virus |
| 01/09/2013 | EP2543369A2 Solution for peritoneal dialysis |
| 01/09/2013 | EP2543368A1 Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| 01/09/2013 | EP2543367A1 Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| 01/09/2013 | EP2543366A1 Film preparation containing medicament with unpleasant taste |
| 01/09/2013 | EP2543364A1 Formulations of cetyl myristate and/or cetyl palmitate |
| 01/09/2013 | EP2543363A1 Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts |
| 01/09/2013 | EP2543362A1 Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts |
| 01/09/2013 | EP2543361A1 Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts |
| 01/09/2013 | EP2543350A1 Adhesive hydrous gel sheet |
| 01/09/2013 | EP2542681A2 Protein and nucleic acid delivery vehicles, components and mechanisms thereof |
| 01/09/2013 | EP2542678A1 A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
| 01/09/2013 | EP2542677A1 Molecular targets for healing or treating wounds |
| 01/09/2013 | EP2542591A2 Silyl-derivatives of polysaccharides |
| 01/09/2013 | EP2542560A2 Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport |
| 01/09/2013 | EP2542554A1 Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| 01/09/2013 | EP2542552A1 Substituted aza-bicyclic imidazole derivatives useful as trpm8 receptor modulators |
| 01/09/2013 | EP2542547A2 Compounds, compositions, formulations and their uses in the treatment of diseases related to copper retention or hepatic disorders |
| 01/09/2013 | EP2542546A1 Process for the preparation of a polymorph of strontium ranelate |
| 01/09/2013 | EP2542545A1 Inhibitors of hepatitis c virus ns5b polymerase |
| 01/09/2013 | EP2542544A1 Ketobenzofuran derivatives, method for synthesising same, and intermediates |
| 01/09/2013 | EP2542542A1 Isotopically enriched arylsulfonamide ccr3 antagonists |
| 01/09/2013 | EP2542540A1 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid |
| 01/09/2013 | EP2542539A1 Tetrazole compounds which selectively modulate the cb2 receptor |
| 01/09/2013 | EP2542537A1 Novel compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (ror gamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune disease |
| 01/09/2013 | EP2542536A1 Morpholino substituted urea derivatives as mtor inhibitors |
| 01/09/2013 | EP2542535A1 Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
| 01/09/2013 | EP2542534A1 Deuterated tetrahydronaphthalene derivatives |
| 01/09/2013 | EP2542529A1 Urethanes, ureas, amidines and related inhibitors of factor xa |
| 01/09/2013 | EP2542528A1 Heterocyclic amides as rock inhibitors |
| 01/09/2013 | EP2542524A1 Derivatives of aminoindanes, their preparation and their application in therapeutics |
| 01/09/2013 | EP2542307A1 Radiotherapy combined with hypoxic cell sensitizers |
| 01/09/2013 | EP2542305A2 Enhanced anti-microbial pdt |
| 01/09/2013 | EP2542263A2 Ep1 inhibition |
| 01/09/2013 | EP2542255A1 Methods and compositions for treating degos' disease |
| 01/09/2013 | EP2542254A1 Secondary structure stabilized nmda receptor modulators and uses thereof |
| 01/09/2013 | EP2542248A1 Polyamine-dihydroxybenzoic acid conjugate hydrogels as iron chelators |
| 01/09/2013 | EP2542247A1 Nucleic acids for targeting multiple regions of the hcv genome |
| 01/09/2013 | EP2542246A1 Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
| 01/09/2013 | EP2542245A1 Antimicrobial cationic stereoids and methods of use |
| 01/09/2013 | EP2542244A1 Use of meloxicam for the long-term treatment of kidney disorders in cats |
| 01/09/2013 | EP2542243A2 Modified release dosage form |
| 01/09/2013 | EP2542242A1 A3ar agonists for the treatment of uveitis |
| 01/09/2013 | EP2542241A2 Methods and compositions for treating or preventing symptoms of hormonal variations |
| 01/09/2013 | EP2542240A1 Compositions and methods for treating viral diseases |
| 01/09/2013 | EP2542239A1 Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same |
| 01/09/2013 | EP2542238A1 Compounds for immunoproteasome inhibition |
| 01/09/2013 | EP2542237A1 Paraconic acids as pigmentation activators |
| 01/09/2013 | EP2542236A1 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients |
| 01/09/2013 | EP2542235A1 Use of riluzole to treat or prevent the adverse effects of antineoplastic agents |
| 01/09/2013 | EP2542234A2 Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
| 01/09/2013 | EP2542233A1 Composition comprising as active ingredient l-carnitine in combination with hydroxykynurennine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation |
| 01/09/2013 | EP2542232A2 Fatty acid inhibitors |
| 01/09/2013 | EP2542231A1 Novel pharmaceutical composition for the treatment of neurodegenerative or neurovascular diseases |
| 01/09/2013 | EP2542229A2 Stabilized pharmaceutical composition |
| 01/09/2013 | EP2542225A2 Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect. |
| 01/09/2013 | EP2542224A1 Dabigatran etexilate-containing oral pharmaceutical composition |
| 01/09/2013 | EP2542223A2 Complex formulation for oral administration comprising probiotic formulation and 5-ht4 receptor agonist and method for the preparation thereof |
| 01/09/2013 | EP2542222A2 Melt-coated pharmaceutical forms |
| 01/09/2013 | EP2542220A2 Use of levodopa, carbidopa and entacapone for treating parkinson's disease |
| 01/09/2013 | EP2542218A1 Use of ellagic acid as an anti-dandruff agent |
| 01/09/2013 | EP2542214A1 Cosmetic anti-ageing composition, corresponding use and application method |
| 01/09/2013 | EP2542211A2 Antimicrobial oil-in-water emulsion containing quaternary ammonium compounds |
| 01/09/2013 | EP2542156A2 Anti-coagulant infusion fluid source |
| 01/09/2013 | EP2542155A2 Cancer diagnosis and imaging |
| 01/09/2013 | EP2542087A1 Biocidal composition and method |
| 01/09/2013 | EP2542086A1 Compounds and therapeutic uses thereof |
| 01/09/2013 | EP2542085A1 Compounds useful for treating neurodegenerative disorders |
| 01/09/2013 | EP2542084A1 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| 01/09/2013 | EP2542081A1 Compounds for treatment of cancer |
| 01/09/2013 | EP2542080A1 Treatment of lupus arthritis using laquinimod |
| 01/09/2013 | EP2542079A1 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| 01/09/2013 | EP2542078A1 Treatment of lupus nephritis using laquinimod |
| 01/09/2013 | EP2542077A1 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| 01/09/2013 | EP2542076A1 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| 01/09/2013 | EP2542074A1 Combination pharmaceutical agents as inhibitors of hcv replication |
| 01/09/2013 | EP2542060A1 Compositions and methods for treating and/or preventing cardiovascular disease |
| 01/09/2013 | EP2542059A1 Compositions comprising myristic acid and uses thereof |
| 01/09/2013 | EP2542058A1 Effective sensitizing dose of a gelled immunomodulating topical composition |
| 01/09/2013 | CN1972668B Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
| 01/09/2013 | CN1876657B Stabilization of macrolides |
| 01/09/2013 | CN1642570B Stable pharmaceutical composition containing factor viii |
| 01/09/2013 | CN102869777A Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 |
| 01/09/2013 | CN102869776A Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF |
| 01/09/2013 | CN102869774A Compositions for targeted delivery of sirna |
| 01/09/2013 | CN102869669A Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 01/09/2013 | CN102869667A Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| 01/09/2013 | CN102869666A Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 01/09/2013 | CN102869665A Benzazepine compound |
| 01/09/2013 | CN102869664A Pyrazolopyrimidine kinase inhibitors |
| 01/09/2013 | CN102869663A Pyrazolopyrazine kinase inhibitors |
| 01/09/2013 | CN102869661A Anti-infective compounds |
| 01/09/2013 | CN102869660A Aminothiazolones as estrogen related receptor-alpha modulators |
| 01/09/2013 | CN102869658A Modulators of fatty acid amide hydrolase |
| 01/09/2013 | CN102869657A Analogues for the treatment or prevention of flavivirus infections |
| 01/09/2013 | CN102869656A Tetrahydrobenzothiophene compound |